MedTrace Logo

A Study To Compare The Pharmacokinetics Of Different Formulations Of PF-04937319 In Healthy Subjects

NCT01513928 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2012-03-12

No results posted yet for this study

Summary

This study is designed to compare the pharmacokinetics of three different formulations of Pf-04937319

Conditions

  • Healthy

Interventions

DRUG

Pf-04937319

Formulation A) Pf-04937319 50 mg - administered as tablet

DRUG

Pf-04937319

Formulation B) Pf-04937319 50 mg - administered as capsule

DRUG

Pf-04937319

Formulation C) Pf-04937319 50 mg - administered as capsule

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation
NA
Purpose
BASIC_SCIENCE
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
21 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2012-01-31
Primary Completion
2012-02-29
Completion
2012-02-29

Countries

  • Singapore

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01513928 on ClinicalTrials.gov